

## **Overestimation of anticoagulant benefit in patients with atrial fibrillation and low life expectancy: evidence from 12 randomized trials**

Sachin J. Shah, MD, MPH (1); Carl van Walraven, MD, MSc (2); Sun Young Jeon, PhD (3); W. John Boscardin, PhD (3, 4); FD Richard Hobbs, FMedSci (5), Stuart Connolly, MD (6); Michael Ezekowitz MB, ChB, DPhil (7); Kenneth E. Covinsky, MD, MPH (3); Margaret C. Fang, MD, MPH (3), Daniel E. Singer, MD (1)

- (1) Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- (2) Departments of Medicine and Epidemiology & Community Medicine, University of Ottawa, Ottawa ON, CA
- (3) Department of Medicine, University of California San Francisco, San Francisco, CA, USA
- (4) Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, USA
- (5) Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford UK
- (6) Population Health Research Institute, McMaster University, Hamilton, ON, Canada
- (7) Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA and Cardiovascular Medicine, Lankenau Institute for Medical Research, Wynnewood, PA, USA

### Corresponding Author

Sachin J. Shah, MD, MPH

100 Cambridge Street, Suite 1600

Boston, MA 02114

[sshah@mgh.harvard.edu](mailto:sshah@mgh.harvard.edu)

617-977-4871

Manuscript: 2939 words

Abstract: 320 words

Preprint (medRxiv): <https://doi.org/10.1101/2023.02.10.23285303>

1 **ABSTRACT**

2 **Background:** Patients with atrial fibrillation (AF) have a high rate of all-cause mortality that is  
3 only partially attributable to vascular outcomes. While the competing risk of death may affect  
4 expected anticoagulant benefit, guidelines do not account for it. We sought to determine if using  
5 a competing risks framework materially affects the guideline-endorsed estimate of absolute risk  
6 reduction attributable to anticoagulants.

7 **Methods:** We conducted a secondary analysis of 12 RCTs that randomized patients with AF to  
8 oral anticoagulants or either placebo or antiplatelets. For each participant, we estimated the  
9 absolute risk reduction (ARR) of anticoagulants to prevent stroke or systemic embolism using  
10 two methods. First, we estimated the ARR using a guideline-endorsed model (CHA<sub>2</sub>DS<sub>2</sub>-VASc)  
11 and then again using a Competing Risk Model that uses the same inputs as CHA<sub>2</sub>DS<sub>2</sub>-VASc but  
12 accounts for the competing risk of death and allows for non-linear growth in benefit over time.  
13 We compared the absolute and relative differences in estimated benefit and whether the  
14 differences in estimated benefit varied by life expectancy.

15 **Results:** 7933 participants had a median life expectancy of 8 years (IQR 6, 12), determined by  
16 comorbidity-adjusted life tables. 43% were randomized to oral anticoagulation (median age 73  
17 years, 36% women). The guideline-endorsed CHA<sub>2</sub>DS<sub>2</sub>-VASc model estimated a larger ARR  
18 than the Competing Risk Model (median ARR at 3 years, 6.9% vs. 5.2%). ARR differences  
19 varied by life expectancies: for those with life expectancies in the highest decile, 3-year ARR  
20 difference (CHA<sub>2</sub>DS<sub>2</sub>-VASc model – Competing Risk Model 3-year risk) was -1.2% (42%  
21 relative underestimation); for those with life expectancies in the lowest decile, 3-year ARR  
22 difference was 5.9% (91% relative overestimation).

23 **Conclusion:** Anticoagulants were exceptionally effective at reduced stroke risk. However,  
24 anticoagulant benefits were misestimated with CHA<sub>2</sub>DS<sub>2</sub>-VASc, which does not account for the

25 competing risk of death nor decelerating treatment benefit over time. Overestimation was most  
26 pronounced in patients with the lowest life expectancy and when benefit was estimated over a  
27 multi-year horizon.

## 28 INTRODUCTION

29 Anticoagulants are the mainstay of preventative therapy for millions of older adults with  
30 atrial fibrillation. While anticoagulants reduce the risk of ischemic stroke and systemic embolism,  
31 they also increase the risk of bleeding. To help patients and clinicians weigh the risks and  
32 benefits of treatment, clinical guidelines and decision support tools endorse using the CHA<sub>2</sub>DS<sub>2</sub>-  
33 VASc score to estimate a patient's annual risk of ischemic stroke or systemic embolism without  
34 treatment.<sup>1-5</sup> The ACC/AHA/HRS consensus guidelines recommend that this baseline risk be  
35 used to estimate a patient's expected absolute risk reduction by applying the relative risk  
36 reduction from a meta-analysis of randomized trials.<sup>1,6</sup> Guidelines recommend anticoagulant  
37 therapy when the absolute risk reduction exceeds a threshold. The premise is that treatment  
38 benefits outweigh risks when an individual's estimated event risk exceeds this threshold.

39 While transparent, this approach makes two assumptions that can affect the accuracy of  
40 expected benefit. First, this approach does not account for the competing risk of death. A  
41 competing risk is an alternative outcome that occurs before, and necessarily precludes, the  
42 event of interest (e.g., cancer death before stroke from atrial fibrillation), thus limiting the  
43 absolute benefit achievable by anticoagulant treatment.<sup>7-11</sup> Competing risks are germane given  
44 the high all-cause mortality rate following a new diagnosis of atrial fibrillation—multiple studies  
45 estimate 20-25% mortality in the first year.<sup>12-14</sup> Second, this approach assumes that the  
46 therapeutic benefit continues to increase at a constant rate over time—that is, the risk of stroke  
47 over two years is twice the one-year risk and thus the absolute risk reduction over two years is  
48 twice the one-year absolute risk reduction. Both issues are readily addressed by estimating  
49 benefit using a competing risk model; however, it is unknown if doing so will materially affect  
50 absolute risk reduction estimates attributable to anticoagulants.

51 We used patient-level data from 12 randomized trials of anticoagulants for atrial  
52 fibrillation to determine if a competing risk model affects the measurement of absolute stroke

53 risk reduction. First, we compared the guideline-endorsed approach to measuring absolute risk  
54 reduction (i.e., CHA<sub>2</sub>DS<sub>2</sub>-VASc score) to a competing risk model (i.e., Fine-Gray model<sup>15</sup>).  
55 Second, we determined if differences in expected stroke risk reduction between the guideline-  
56 endorse CHA<sub>2</sub>DS<sub>2</sub>-VASc approach and a competing risk model varied by life expectancy.

57

## 58 **METHODS**

### 59 **Study design and participants**

60 We used patient-level data from the Atrial Fibrillation Investigators (AFI) database which  
61 contains patient-level data from 12 published clinical trials where patients were randomized to  
62 full-dose oral anticoagulant, antiplatelets, or placebo. We focused on trials that established the  
63 efficacy of oral anticoagulants; therefore, we did not include trials that compared two different  
64 oral anticoagulants. We included the following trials: Atrial Fibrillation, Aspirin, and  
65 Anticoagulation Study 1 (AFASAK-1),<sup>16</sup> AFASAK-2,<sup>17</sup> Boston Area Anticoagulation Trial for Atrial  
66 Fibrillation (BAATAF),<sup>18</sup> Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA),<sup>19</sup>  
67 Canadian Atrial Fibrillation Anticoagulation (CAFA),<sup>20</sup> European Atrial Fibrillation Trial (EAFT),<sup>21</sup>  
68 Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation (PAATAF),<sup>22</sup> National  
69 Study for Prevention of Embolism in Atrial Fibrillation (NASPEAF),<sup>23</sup> the Stroke Prevention in  
70 Atrial Fibrillation 1 (SPAF-1),<sup>24</sup> SPAF-2,<sup>25</sup> SPAF-3,<sup>26</sup> and Stroke Prevention in Non-rheumatic  
71 Atrial Fibrillation (SPINAF).<sup>27</sup> We did not include patients with mitral stenosis and patients in  
72 SPAF-1, EAFT, PATAF, and SPAF-3 who were deemed ineligible to receive anticoagulants  
73 (trial details in **Appendix 1** and **Appendix 2**).

## 74 **Participant characteristics**

75           Research coordinators and physicians collected patient characteristics before therapy  
76 initiation. While specific features varied from study to study, common elements included a  
77 history of stroke or transient ischemic attack, hypertension or systolic blood pressure  $\geq 160$   
78 mmHg or use of antihypertensives, diabetes, angina, myocardial infarction, peripheral vascular  
79 disease, smoking, and congestive heart failure, and body mass index. History of myocardial  
80 infarction was not collected in NASPEAF and peripheral vascular disease was not collected in  
81 AFASAK1, BAATAF, or BAFTA. Because history of myocardial infarction and peripheral  
82 vascular disease were missing for all participants in specific trials, we assumed they were  
83 missing at random and imputed them in 20 datasets using chained equations.<sup>28</sup> We excluded  
84 <1% of participants who were missing data otherwise collected in a given trial (**Appendix 3**).

85

## 86 **Treatment exposure**

87           We examined all patients based on their treatment allocation (i.e., intention to treat).  
88 Because studies have shown that antiplatelet and low-dose warfarin are ineffective  
89 thromboprophylaxis in AF,<sup>6</sup> we categorized all trial participants as being randomized to full-dose  
90 anticoagulants or control. Patients randomized to placebo, antiplatelets, low-dose warfarin, or  
91 low-dose warfarin with aspirin were considered controls. AFASAK2, PAATAF, and SPAF3 used  
92 low-dose warfarin and reported a mean international normalized ratio (INR) of < 1.5 supporting  
93 their categorization as a control. While NASPEAF also had a low-dose anticoagulant arm, the  
94 mean INR was 2.0 which is considered therapeutic<sup>1</sup>; therefore, we excluded participants  
95 randomized to the NASPEAF low-dose anticoagulant arm.

96 **Outcome ascertainment**

97           The primary outcome was ischemic stroke or systemic embolism. We detail outcome  
98 definitions by trial in **Appendix 4**. In general, trials defined ischemic stroke as a focal  
99 neurological deficit lasting >24 hours. All trials except AFASAK-1 required a CT or MRI showing  
100 the absence of blood. Systemic embolism was collected as an outcome in all but SPINAF and,  
101 by and large, defined as an embolism to internal organs or limbs and required evidence via  
102 angiography, surgery, or autopsy (**Appendix 4**). Patients were evaluated at 3- to 6-month  
103 intervals or when a clinical outcome event was suspected. Except in AFASAK-1, a central  
104 committee, blinded to intervention allocation, adjudicated all clinical events.

105

106 **Life expectancy**

107           We estimated the life expectancy of each participant at the time of trial enrollment using  
108 the life table method.<sup>29</sup> We started with gender- and enrollment year-specific life tables from the  
109 U.S. Centers for Disease Control and Prevention.<sup>30</sup> These tables, generated from population  
110 data, predict annual mortality rates stratified by age, sex, and year. The life table method uses  
111 annual mortality rates to calculate life expectancy. We used the life table method to estimate  
112 each participant's life expectancy by adjusting the annual mortality rate for the additional  
113 mortality risk associated with their comorbidities at the time of trial enrollment (**Appendix 5**).

114

115 **Analysis**

116           Our first analytic goal was to determine if using a competing risk framework generates  
117 estimates of stroke risk reduction different from those of the guideline-endorsed CHA<sub>2</sub>DS<sub>2</sub>-VASc  
118 model. To accomplish this and speak directly to guideline-recommended practice, we estimated  
119 absolute risk reduction using the CHA<sub>2</sub>DS<sub>2</sub>-VASc score as the ACC/AHA/HRS guidelines

120 recommend.<sup>1,2</sup> Specifically, we assigned each patient an off-treatment risk of ischemic stroke or  
121 systemic embolism corresponding to their CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Rates come from the 2012  
122 study by Friberg et al., which used the Swedish Atrial Fibrillation cohort to validate off-treatment  
123 thromboembolic rates corresponding to each CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>31</sup> These rates are used in  
124 patient-facing decision tools, online calculators, and decision analytic models.<sup>5,32,33</sup> To calculate  
125 the absolute risk reduction, we multiplied the off-treatment stroke rate by 0.64, the guideline-  
126 cited efficacy of anticoagulants.<sup>1,6</sup> Using this procedure for each patient, we estimated the  
127 annual absolute risk reduction; this precise method is endorsed by the ACC/AHA/HRS Atrial  
128 Fibrillation management guidelines to estimate benefit.<sup>1</sup> Because patients and physicians prefer  
129 to make anticoagulant decisions using a 1-to-5-year time horizon,<sup>5</sup> we extrapolated this annual  
130 reduction over five years, accounting for the declining at-risk population (**Appendix 6**).<sup>34,35</sup> The  
131 same approach is also used in decision aids.<sup>5</sup>

132         Next, we estimated the absolute risk reduction using the Fine-Gray extension of the Cox  
133 proportional hazards model, treating death unrelated to ischemic stroke or systemic embolism  
134 as a competing event.<sup>11</sup> We fit a Fine-Gray model where time to ischemic stroke or systemic  
135 embolism is a function of age (<65 years, 65-74 years, >75years), gender, congestive heart  
136 failure, diabetes, hypertension, prior stroke or transient ischemic attack, and vascular disease  
137 stratified by randomization to oral anticoagulants. These the same predictors used in the  
138 CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Then, we used the resulting treatment-stratified models to estimate the  
139 cumulative incidence of ischemic stroke or systemic embolism for each participant given their  
140 covariates at each study time point, assuming first they had been randomized to oral  
141 anticoagulants and then assuming they had been randomized to control (i.e., predicted  
142 values).<sup>36,37</sup> The difference between the two estimates represented the ARR for a given patient  
143 at a given time point. We determined the misestimation of the CHA<sub>2</sub>DS<sub>2</sub>-VASc method as the  
144 difference between the ARR estimated by CHA<sub>2</sub>DS<sub>2</sub>-VASc and the ARR estimated by the



145 Competing Risk Model. We used the paired t-test to determine if the two methods produced  
146 statistically different estimates of benefit at each year after randomization.

147 Our second analytic goal was to determine if life expectancy predicted magnitude in the  
148 CHA<sub>2</sub>DS<sub>2</sub>-VASc model misestimation. To achieve this, we determined the association between  
149 life expectancy and misestimation of the CHA<sub>2</sub>DS<sub>2</sub>-VASc method over a 3-year horizon. We  
150 chose 3 years since it is the midpoint between the 1-to-5 year horizon preferred by patients and  
151 physicians and has been used in prior anticoagulation decision analyses.<sup>5,38</sup> We examined  
152 misestimation of the CHA<sub>2</sub>DS<sub>2</sub>-VASc method by decile of life expectancy at trial enrollment,  
153 hypothesizing that the misestimation would be greater at lower life expectancies.

154 We performed all statistical analyses using SAS 9.4 (Cary, NC). The study protocol was  
155 approved by Institutional Review Boards at UCSF (21-34930) and MGH (2022P001783).

156

## 157 **RESULTS**

### 158 **Patient characteristics and overall event rates**

159 This study included 7933 patients from 12 randomized trials where 3407 (43%) were  
160 randomized to oral anticoagulation (**Table 1**). The median age was 73 years at enrollment, 36%  
161 were women, and the median CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 3 [IQR 2, 4]. At enrollment, the  
162 median life expectancy was 8 years [IQR 6, 12] (**Appendix 7**). Most patients (83%) ended the  
163 follow-up period without a clinical event (median 731 days; IQR 415, 1025). (**Table 2**). In these  
164 trials, 530 (7%) patients' first clinical event was an ischemic stroke or systemic embolism  
165 (median 334 days; IQR 120, 580). Additionally, 630 (8%) patients died before a stroke or  
166 systemic embolism (median 457 days; IQR 216, 772).

## 167 **Comparison of absolute risk reduction estimates**

168           Relative to the Competing Risk Model, the CHA<sub>2</sub>DS<sub>2</sub>-VASc model overestimated the  
169 absolute risk reduction (ARR) of anticoagulants (**Figure 1**). As the time horizon increased, the  
170 CHA<sub>2</sub>DS<sub>2</sub>-VASc estimate of median benefit increased linearly. In contrast, the Competing Risk  
171 Model estimated a non-linear absolute risk reduction over time—while benefit increased over  
172 time, it decelerated, i.e., absolute risk reduction grew by less each year. As a result, the  
173 CHA<sub>2</sub>DS<sub>2</sub>-VASc model overestimated anticoagulation benefit as the time-horizon increased.  
174 After 1 year, the CHA<sub>2</sub>DS<sub>2</sub>-VASc model and the Competing Risk Model produced clinically  
175 similar estimates of absolute risk reduction (median ARR 2.3% by CHA<sub>2</sub>DS<sub>2</sub>-VASc estimate vs.  
176 2.4% by Competing Risk Model,  $p < 0.001$ ). After 3 years, the CHA<sub>2</sub>DS<sub>2</sub>-VASc-based ARR was  
177 clinically and statistically larger than the ARR from the Competing Risk Model (median ARR  
178 6.9% vs. 5.2%,  $p < 0.001$ ). This difference increased when absolute risk reduction was estimated  
179 over a 5-year horizon (median ARR 11.2% vs. 6.3%,  $p < 0.001$ ).

180           We assess whether the observed discrepancy in ARR could be because the guidelines  
181 estimate of off-treatment stroke risk were produced in an external cohort and therefore were  
182 miscalibrated (**Appendix 9**). The sensitivity showed that recalibration to the AFI database did  
183 not meaningfully change the results presented in **Figure 1**.

184

## 185 **Life expectancy and misestimation of benefit**

186           As life expectancy decreased, the CHA<sub>2</sub>DS<sub>2</sub>-VASc model increasingly overestimated the  
187 stroke and systemic embolism risk reduction attributable to anticoagulants in absolute and  
188 relative terms (**Figure 2**). The figure plots the absolute and relative difference between the 3-  
189 year ARR estimated by the CHA<sub>2</sub>DS<sub>2</sub>-VASc model and the Competing Risk Model by life  
190 expectancy decile at trial enrollment. In the decile with the highest life expectancy (16 to 47

191 years), on average, over 3 years, the CHA<sub>2</sub>DS<sub>2</sub>-VAsC model underestimated benefit by 1.2%  
192 (95% CI 1.1% to 1.3%) in absolute terms and 42% (95% CI 40% to 45%) in relative terms. By  
193 comparison, in the decile with the lowest life expectancy (1 to 4 years), on average over 3  
194 years, the CHA<sub>2</sub>DS<sub>2</sub>-VAsC model overestimated benefit by 5.9% (95% CI 5.6% to 6.1%) in  
195 absolute terms and 91% (95% CI 87% to 95%) in relative terms.

196

## 197 **DISCUSSION**

198 Using patient-level data from 12 randomized trials, we demonstrated that while  
199 anticoagulants effectively reduce ischemic stroke and systemic embolism risk, failing to use a  
200 competing risks framework resulted in a meaningful overestimation of treatment benefit. This  
201 finding was most pronounced when risk reduction was estimated over a multi-year horizon.  
202 Further, we showed that as life expectancy decreased, treatment benefit was increasingly  
203 overestimated. While those with the highest life expectancy may benefit more than guideline  
204 estimates would suggest, benefit for those with the lowest life expectancy was strikingly  
205 overestimated.

206 The study results directly apply to the AHA/ACC/HRS<sup>1,2</sup> and European Society of  
207 Cardiology (ESC)<sup>3</sup> atrial fibrillation guidelines in which the cornerstone of anticoagulant  
208 decision-making is estimating the absolute risk reduction. Guidelines ask clinicians to estimate  
209 the off-treatment stroke risk using the CHA<sub>2</sub>DS<sub>2</sub>-VAsC score and to use that baseline risk to  
210 infer the probable absolute risk reduction. Anticoagulants are recommended above a CHA<sub>2</sub>DS<sub>2</sub>-  
211 VAsC score threshold—i.e., when the absolute risk reduction exceeds a threshold. Thus, if  
212 clinical guidelines continue to recommend treatment using an absolute risk reduction threshold,  
213 these results suggest guidelines should re-estimate benefit using a competing risk framework.

214 At the very least, guidelines should acknowledge that current methods overestimate benefits for  
215 those with limited life expectancy and when estimating benefits over a multi-year horizon.

216 The current study's findings should influence anticoagulant decision aids for patients  
217 with atrial fibrillation. To advance anticoagulant shared decision-making, investigators and  
218 professional societies have developed conversation aids that display a patient's risk of stroke  
219 with and without anticoagulants. For example, the American College of Cardiology's  
220 CardioSmart tool and the Mayo Clinic Anticoagulation Choice Decision Aid both display a  
221 pictogram of absolute risk with and without treatment to communicate treatment effects.<sup>4,5</sup>  
222 These implementation tools are built to reflect clinical guidelines and do so faithfully. However,  
223 both should note that benefit estimates are overstated for those with limited life expectancy and  
224 when benefit is estimated over a multi-year horizon.

225 These results also lend credence to physicians for whom advanced age, frailty, and  
226 function—all significant determinants of life expectancy—factor in their anticoagulant decision-  
227 making.<sup>39,40</sup> Adults aged 65 years and older constitute 80% of all American adults with atrial  
228 fibrillation.<sup>41</sup> Further, prior work indicates that many older adults with atrial fibrillation have  
229 geriatric syndromes (e.g., dependency in activities of daily living) known to be associated with a  
230 reduced life expectancy.<sup>42,43</sup> In this study, we estimated life expectancy using basic medical  
231 comorbidity data available in the trial database. Modern, more accurate tools go beyond  
232 comorbidities using physical function, cognition, and self-reported health to estimate life  
233 expectancy.<sup>44,45</sup> Life expectancy estimates from such tools are routinely used to inform the risk  
234 and benefits of interventions in older adults (e.g., cancer screening). Until guidelines formally  
235 account for it, clinicians may consider using life expectancy to guide the discussion about the  
236 benefit of anticoagulants when treating older adults. This may be particularly relevant when  
237 treating patients with both a limited life expectancy and borderline CHA<sub>2</sub>DS<sub>2</sub>-VASc scores.

238 Finally, these findings should inform the methods used to develop and validate future  
239 stroke risk models. While the CHA<sub>2</sub>DS<sub>2</sub>-VASc score continues to be endorsed by U.S. and  
240 European guidelines, investigators are actively developing a new generation of stroke risk  
241 prediction models. Contemporary models like the ABC stroke risk score, CARS, and the ATRIA  
242 stroke model all outperform the CHA<sub>2</sub>DS<sub>2</sub>-VASc score.<sup>46–48</sup> However, none used an analysis  
243 framework that both accounts for the competing risk of death and changing risk over a multi-  
244 year horizon. The ABC model establishes a non-linear stroke risk by showing 3-year risk is not  
245 simply three times the 1-year risk, findings that were redemonstrated in this paper. When  
246 developing the ABC model, Hijazi et al. also conducted a sensitivity analysis comparing their  
247 model to a competing risk model.<sup>46</sup> They found a tight correlation when risk was estimated over  
248 a 1-year horizon, results mirrored in this study. We expanded on their work by showing that this  
249 correlation was weaker when using a longer time horizon (e.g., 3 years). More importantly, we  
250 identified substantial heterogeneity—as life expectancy decreased, overestimation increased.

251 There are limitations to this study inherent to the data available and the study design.  
252 First, this study relied on data from RCTs conducted between 1989 and 2007 and thus may be  
253 only partially representative of contemporary patients with atrial fibrillation. Specific differences  
254 include the risk of stroke and death from non-atrial fibrillation causes and the added safety of  
255 direct-acting anticoagulants.<sup>49</sup> This limitation is balanced by the fact that the AFI cohort is one of  
256 the largest patient-level atrial fibrillation cohorts where anticoagulant treatment was randomized  
257 against placebo and antiplatelets. The results were unaffected by selection bias that hampers  
258 contemporary risk models developed in observational cohorts. More importantly, while dated,  
259 these trials are the foundation upon which current guidelines recommend anticoagulants.  
260 Second, this study could not address the relationship between life expectancy and the potential  
261 misestimation of anticoagulant harm. Specifically, the AF Investigators database does not  
262 include inputs used in contemporary hemorrhage prediction tools (e.g., ATRIA bleed, HAS-

263 BLED). While it is important to consider the effect a competing risk framework may have on  
264 estimating the risk of bleeding, current guidelines do not incorporate bleeding risk into treatment  
265 recommendations. For example, for patients with scores above the CHA<sub>2</sub>DS<sub>2</sub>-VASc treatment  
266 threshold, guideline recommendations do not change whether the bleeding risk is high or low.  
267 Finally, because nationality was unavailable for study participants, we relied on U.S. life tables  
268 to calculate life expectancy.

269         In summary, we showed that while oral anticoagulants were clearly effective, treatment  
270 benefit was overstated when using the guideline-endorsed approach because guidelines do not  
271 account for the competing risk of death and assume a constant growth in treatment benefit over  
272 time. Overestimation was most pronounced in patients with the lowest life expectancy and when  
273 benefit was estimated over a multi-year horizon. These findings should inform guidelines and  
274 decision aids, clinicians treating patients with limited life expectancy, and investigators  
275 developing stroke risk prediction models.

## **ACKNOWLEDGMENTS**

We thank Dr. Sei Lee, Professor of Medicine at UCSF, for his valuable methodological feedback. Dr. Shah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Author contributions:** Dr. Shah had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors listed have contributed sufficiently to the project to be included as authors, and all those who are qualified to be authors are listed in the author byline.

**Conflict of Interest Disclosure:** Dr. Shah, Dr. Jeon, Dr. Boscardin, and Dr. Covinsky reported funding from the National Institute on Aging/National Institutes of Health related to the conduct of this study (noted below). Dr. Fang reported grants from the National Heart, Lung, and Blood Institute/National Institutes of Health during the conduct of the study (K24HL141354) and grants from Patient-Centered Outcomes Research Institute outside the submitted work. Dr. Singer was supported, in part, by the Eliot B. and Edith C. Shoolman Fund of Massachusetts General Hospital. He has received research support from Bristol Myers Squibb and consultancy fees from Bristol-Myers Squibb, Fitbit, Medtronic, and Pfizer. Professor Hobbs is, in part, supported by the NIHR (ARC OTV and MIC) and has received occasional consultancy fees from Bayer, BMS Pfizer, Novartis, and AZ unconnected to this study.

**Funding:** This study was funded by the NIA (K76AG074919, P30AG044281).

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data sharing:** Researchers can apply to the AF Investigators for data access.

## REFERENCES

- 276 1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline  
277 for the Management of Patients With Atrial Fibrillation: A Report of the American College of  
278 Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart  
279 Rhythm Society. *J Am Coll Cardiol*. 2014;64(21):e1-e76. doi:10.1016/j.jacc.2014.03.022
- 280 2. January C, Wann L, Samuel, Calkins Hugh, et al. 2019 AHA/ACC/HRS Focused Update of  
281 the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:  
282 A Report of the American College of Cardiology/American Heart Association Task Force  
283 on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the  
284 Society of Thoracic Surgeons. *Circulation*. 2019;140(2):e125-e151.  
285 doi:10.1161/CIR.0000000000000665
- 286 3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and  
287 management of atrial fibrillation developed in collaboration with the European Association  
288 for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2021;42(5):373-498.  
289 doi:10.1093/eurheartj/ehaa612
- 290 4. Atrial Fibrillation | CardioSmart – American College of Cardiology. CardioSmart. Accessed  
291 December 23, 2020. <http://www.cardiosmart.org/topics/atrial-fibrillation>
- 292 5. Zeballos-Palacios CL, Hargraves IG, Noseworthy PA, et al. Developing a Conversation Aid  
293 to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.  
294 *Mayo Clin Proc*. 2019;94(4):686-696. doi:10.1016/j.mayocp.2018.08.030
- 295 6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke  
296 in Patients Who Have Nonvalvular Atrial Fibrillation. *Ann Intern Med*. 2007;146(12):857-  
297 867. doi:10.7326/0003-4819-146-12-200706190-00007
- 298 7. Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a  
299 review and recommendations for improvement. *Stat Med*. 2017;36(8):1203-1209.  
300 doi:10.1002/sim.7215
- 301 8. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical  
302 community: irrelevance or ignorance? *Stat Med*. 2012;31(11-12):1089-1097.  
303 doi:10.1002/sim.4384
- 304 9. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on  
305 competing risks in survival data analysis. *Br J Cancer*. 2004;91(7):1229-1235.  
306 doi:10.1038/sj.bjc.6602102
- 307 10. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing Risk of Death: An Important  
308 Consideration in Studies of Older Adults. *J Am Geriatr Soc*. 2010;58(4):783-787.  
309 doi:10.1111/j.1532-5415.2010.02767.x
- 310 11. Austin Peter C., Lee Douglas S., Fine Jason P. Introduction to the Analysis of Survival  
311 Data in the Presence of Competing Risks. *Circulation*. 2016;133(6):601-609.  
312 doi:10.1161/CIRCULATIONAHA.115.017719



- 313 12. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial  
314 Fibrillation on the Risk of Death: The Framingham Heart Study. *Circulation*.  
315 1998;98(10):946-952. doi:10.1161/01.CIR.98.10.946
- 316 13. Piccini Jonathan P., Hammill Bradley G., Sinner Moritz F., et al. Incidence and Prevalence  
317 of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993–2007.  
318 *Circ Cardiovasc Qual Outcomes*. 2012;5(1):85-93.  
319 doi:10.1161/CIRCOUTCOMES.111.962688
- 320 14. Siontis KC, Gersh BJ, Weston SA, et al. Associations of Atrial Fibrillation After Noncardiac  
321 Surgery With Stroke, Subsequent Arrhythmia, and Death: A Cohort Study. *Ann Intern Med*.  
322 Published online July 26, 2022:M22-0434. doi:10.7326/M22-0434
- 323 15. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing  
324 Risk. *J Am Stat Assoc*. 1999;94(446):496-509. doi:10.2307/2670170
- 325 16. Petersen P, Godtfredsen J, Boysen G, Andersen E, Andersen B. PLACEBO-  
326 CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR  
327 PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL  
328 FIBRILLATION: The Copenhagen AFASAK Study. *The Lancet*. 1989;333(8631):175-179.  
329 doi:10.1016/S0140-6736(89)91200-2
- 330 17. Gulløv AL, Koefoed BG, Petersen P, et al. Fixed Minidose Warfarin and Aspirin Alone and  
331 in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation:  
332 Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. *Arch Intern  
333 Med*. 1998;158(14):1513-1521. doi:10.1001/archinte.158.14.1513
- 334 18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Singer DE, Hughes  
335 RA, et al. The effect of low-dose warfarin on the risk of stroke in patients with  
336 nonrheumatic atrial fibrillation. *N Engl J Med*. 1990;323(22):1505-1511.  
337 doi:10.1056/NEJM199011293232201
- 338 19. Mant J, Hobbs FR, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an  
339 elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation  
340 Treatment of the Aged Study, BAFTA): a randomised controlled trial. *The Lancet*.  
341 2007;370(9586):493-503. doi:10.1016/S0140-6736(07)61233-1
- 342 20. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial  
343 fibrillation anticoagulation (CAFA) study. *J Am Coll Cardiol*. 1991;18(2):349-355.  
344 doi:10.1016/0735-1097(91)90585-W
- 345 21. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-  
346 rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *The Lancet*.  
347 1993;342(8882):1255-1262. doi:10.1016/0140-6736(93)92358-Z
- 348 22. Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial  
349 thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled  
350 trial comparing two intensities of coumarin with aspirin. *BMJ*. 1999;319(7215):958-964.  
351 doi:10.1136/bmj.319.7215.958

- 352 23. Pérez-Gómez F, Alegría E, Berjón J, et al. Comparative effects of antiplatelet,  
353 anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial  
354 fibrillation: A randomized multicenter study. *J Am Coll Cardiol.* 2004;44(8):1557-1566.  
355 doi:10.1016/j.jacc.2004.05.084
- 356 24. Preliminary Report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med.*  
357 1990;322(12):863-868. doi:10.1056/NEJM199003223221232
- 358 25. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention  
359 of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. *The*  
360 *Lancet.* 1994;343(8899):687-691. doi:10.1016/S0140-6736(94)91577-6
- 361 26. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-  
362 intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke  
363 Prevention in Atrial Fibrillation III randomised clinical trial. *The Lancet.*  
364 1996;348(9028):633-638. doi:10.1016/S0140-6736(96)03487-3
- 365 27. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke  
366 associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in  
367 Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med.* 1992;327(20):1406-1412.  
368 doi:10.1056/NEJM199211123272002
- 369 28. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and  
370 guidance for practice. *Stat Med.* 2011;30(4):377-399. doi:https://doi.org/10.1002/sim.4067
- 371 29. *Method for Constructing Complete Annual U.S. Life Tables.* National Center for Health  
372 Statistics; 1999:36.
- 373 30. The Berkeley Mortality Database. Accessed November 3, 2021. <http://bmd.mortality.org/>
- 374 31. Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic  
375 stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation  
376 cohort study. *Eur Heart J.* 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488
- 377 32. CHA<sub>2</sub>DS<sub>2</sub>-VASc Score for Atrial Fibrillation Stroke Risk - MDCalc. Accessed October 11,  
378 2022. <https://www.mdcalc.com/calc/801/cha2ds2-vasc-score-atrial-fibrillation-stroke-risk>
- 379 33. Eckman MH, Wise RE, Naylor K, et al. Developing an Atrial Fibrillation Guideline Support  
380 Tool (AFGuST) for shared decision making. *Curr Med Res Opin.* 2015;31(4):603-614.  
381 doi:10.1185/03007995.2015.1019608
- 382 34. Miller DK, Homan SM. Determining Transition Probabilities: Confusion and Suggestions.  
383 *Med Decis Making.* 1994;14(1):52-58. doi:10.1177/0272989X9401400107
- 384 35. Rothman KJ. *Epidemiology: An Introduction.* Oxford University Press; 2002.  
385 <https://books.google.com/books?id=f3gltAEACAAJ>
- 386 36. Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating Model-Adjusted Risks, Risk  
387 Differences, and Risk Ratios From Complex Survey Data. *Am J Epidemiol.*  
388 2010;171(5):618-623. doi:10.1093/aje/kwp440

- 389 37. Graubard BI, Korn EL. Predictive Margins with Survey Data. *Biometrics*. 1999;55(2):652-  
390 659. doi:10.1111/j.0006-341X.1999.00652.x
- 391 38. Shah Sachin J., Singer Daniel E., Fang Margaret C., Reynolds Kristi, Go Alan S., Eckman  
392 Mark H. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial  
393 Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2019;12(11):e006212.  
394 doi:10.1161/CIRCOUTCOMES.119.006212
- 395 39. Ashburner JM, Atlas SJ, Khurshid S, et al. Electronic physician notifications to improve  
396 guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. *J Gen  
397 Intern Med*. Published online August 3, 2018. doi:10.1007/s11606-018-4612-6
- 398 40. McGrath ER, Go AS, Chang Y, et al. Use of Oral Anticoagulant Therapy in Older Adults  
399 with Atrial Fibrillation After Acute Ischemic Stroke. *J Am Geriatr Soc*. 2017;65(2):241-248.  
400 doi:10.1111/jgs.14688
- 401 41. Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults:  
402 National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation  
403 and Risk Factors In Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-2375.  
404 doi:10.1001/jama.285.18.2370
- 405 42. Shah SJ, Fang MC, Jeon SY, Gregorich SE, Covinsky KE. Geriatric Syndromes and Atrial  
406 Fibrillation: Prevalence and Association with Anticoagulant Use in a National Cohort of  
407 Older Americans. *J Am Geriatr Soc*. 2021;69(2):349-356. doi:10.1111/jgs.16822
- 408 43. Kane RL, Shamliyan T, Talley K, Pacala J. The Association Between Geriatric Syndromes  
409 and Survival. *J Am Geriatr Soc*. 2012;60(5):896-904. doi:10.1111/j.1532-  
410 5415.2012.03942.x
- 411 44. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and Validation of a Prognostic  
412 Index for 4-Year Mortality in Older Adults. *JAMA*. 2006;295(7):801-808.  
413 doi:10.1001/jama.295.7.801
- 414 45. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to Predict 5-Year  
415 Mortality of Community-Dwelling Adults Aged 65 and Older Using Data from the National  
416 Health Interview Survey. *J Gen Intern Med*. 2009;24(10):1115-1122. doi:10.1007/s11606-  
417 009-1073-y
- 418 46. Hijazi Z, Lindbäck J, Alexander JH, et al. The ABC (age, biomarkers, clinical history) stroke  
419 risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. *Eur Heart  
420 J*. 2016;37(20):1582-1590. doi:10.1093/eurheartj/ehw054
- 421 47. Lee CJY, Toft-Petersen AP, Ozenne B, et al. Assessing absolute stroke risk in patients  
422 with atrial fibrillation using a risk factor-based approach. *Eur Heart J - Cardiovasc  
423 Pharmacother*. 2021;7(F1):f3-f10. doi:10.1093/ehjcvp/pvaa063
- 424 48. Singer DE, Chang Y, Borowsky LH, et al. A New Risk Scheme to Predict Ischemic Stroke  
425 and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. *J  
426 Am Heart Assoc*. 2013;2(3):e000250. doi:10.1161/JAHA.113.000250

- 427 49. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new  
428 oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of  
429 randomised trials. *The Lancet*. 2014;383(9921):955-962.

**Table 1: Characteristics of patients with atrial fibrillation in 12 randomized trials**

<b>Characteristic</b>	<b>n=7933</b>
Age, years (median [IQR])	73 [67, 78]
Gender	
Male	5040 (64%)
Female	2893 (36%)
Diabetes	
No	6780 (85%)
Yes	1153 (15%)
Hypertension	
No	4049 (51%)
Yes	3884 (49%)
Congestive heart failure	
No	5533 (70%)
Yes	2400 (30%)
Prior stroke	
No	6413 (81%)
Yes	1520 (19%)
Angina	
No	6566 (83%)
Yes	1367 (17%)
Prior myocardial infarction	
No	6514 (82%)
Yes	876 (11%)
Missing*	543 (7%)
Peripheral vascular disease	
No	5109 (64%)
Yes	429 (5%)
Missing <sup>†</sup>	2395 (30%)
Body mass index kg/m <sup>2</sup> (median [IQR])	
BMI among those with data	26 [24, 29]
Missing <sup>‡</sup>	2070 (26%)
Smoking status	
Never smoker	2427 (31%)
Former smoker	1843 (23%)
Current smoker	790 (10%)
Missing <sup>§</sup>	2873 (36%)
CHA <sub>2</sub> DS <sub>2</sub> -VASc score	

Score (median [IQR])	3 [2, 4]
Missing <sup>-</sup>	2938 (37%)
Trial	
AFASAK1	1002 (13%)
AFASAK2	677 (9%)
BAATAF	420 (5%)
BAFTA	973 (12%)
CAFA	375 (5%)
EAFT	661 (8%)
NASPEAF	543 (7%)
PATAF	364 (5%)
SPAF1	208 (3%)
SPAF2	1098 (14%)
SPAF3	1044 (13%)
SPINAF	568 (7%)
Randomized study arm assignment	
Warfarin	3407 (43%)
Control <sup>¶</sup>	4526 (57%)

#### Legend

AFASAK - Atrial Fibrillation, Aspirin, and Anticoagulation Study; BAATAF - Boston Area Anticoagulation Trial for Atrial Fibrillation; BAFTA - Birmingham Atrial Fibrillation Treatment of the Aged Study; CAFA - Canadian Atrial Fibrillation Anticoagulation; EAFT - European Atrial Fibrillation Trial; PAATAF - Primary Prevention of Arterial Thromboembolism in Atrial Fibrillation; NASPEAF - National Study for Prevention of Embolism in Atrial Fibrillation; SPAF - Stroke Prevention in Atrial Fibrillation; SPINAF - Stroke Prevention in Non-rheumatic Atrial Fibrillation

\* History of myocardial infarction was not available for NSPEAF trial participants

† History of peripheral vascular disease was not available for AFASAK1, BAATAF, or BAFTA trial participants

‡ Height and weight were not available for BAATAF or AFASAK2 trial participants

§ Smoking status was not available for AFASAK1, CAFA, or BAFTA participants. In EAFT, data collection did not distinguish between former and never smokers

□ CHA<sub>2</sub>DS<sub>2</sub>-VASc scores are for those with complete cases. It excludes 2395 participants enrolled in trials where peripheral vascular disease data are not available, and 543 participants enrolled in trials where history of myocardial infarction was not available.


¶ Control includes those assigned placebo, aspirin, low-dose warfarin, or low-dose warfarin an aspirin. Patients enrolled in SPAF3 and AFASAK2 and assigned to low-dose warfarin had a mean internal normalized ratio (INR) of < 1.5 supporting their categorization as a control. Patients enrolled in NASPEAF and randomized to low-dose anticoagulant had a mean INR of 2.0 and were therefore not included as a control.

Since missing data were missing for entire trials, they were assumed to be missing completely at random.

**Table 2: Trial outcomes, rates and follow-up time**

<b>First clinical outcome</b>	<b>Events (%)</b>	<b>Days from randomization, median (IQR)</b>
Ischemic stroke or systemic embolism	530 (7%)	334 (120, 580)
Systemic bleed	175 (2%)	413 (163, 731)
Intracranial hemorrhage	29 (0%)	300 (201, 620)
Death, all-cause	630 (8%)	457 (216, 772)
Study end without a clinical event	6569 (83%)	731 (415, 1025)

**Figure 1: Estimated median absolute risk reduction by CHA<sub>2</sub>DS<sub>2</sub>-VASc model compared with Competing Risk Model**




#### Legend

For each patient in the cohort, we estimate the absolute risk reduction attributable to oral anticoagulation annually for 5 years using the CHA<sub>2</sub>DS<sub>2</sub>-VASc model and again using a Fine-Gray model, a survival model that accounts for the competing risk of death. We plot the median benefit at each time point. We graphed the median ARR because the CHA<sub>2</sub>DS<sub>2</sub>-VASc model produces discrete estimates of benefit (i.e., not normally distributed). Data are presented as a table in **Appendix 10**. Component on- and off-treatment cumulative incidence rates also displayed in **Appendix 10**.




**Figure 2: Misestimation of Stroke Risk Reduction by CHA<sub>2</sub>DS<sub>2</sub>-VASc score at 3 years,**

**(A) Absolute misestimation**



## (B) Relative misestimation



### Legend

Absolute misestimation is defined as:  $ARR_{CHA2DS2-VASc} - ARR_{Competing Risk Model}$ .

Relative misestimation is defined as:  $ARR_{CHA2DS2-VASc} / ARR_{Competing Risk Model} - 1$ .

The dot represents the mean overestimation, and the error bars represent the 95% confidence interval of the mean. The misestimation of absolute risk reduction (ARR) is calculated for each patient as the difference between the ARR computed by the CHA<sub>2</sub>DS<sub>2</sub>-VASc score and the ARR computed by the Fine-Gray model, a survival model that accounts for the competing risk of death. Positive numbers represent the overestimation of the CHA<sub>2</sub>DS<sub>2</sub>-VASc model. Tabular results can be found in **Appendix 11**.